NOTE: This video is ONLY available to watch in selected countries and geographies [geoip-content country=”AT, BE, BG, HR, CY, CZ, DK, EE, FI, DE, GR, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SK, SI, CH, ES, SE, GB, AL, AD, AM, AZ, BY, BA, GE, IS, KZ, LI, MD, MC, ME, MK, NO, RU, SM, RS, CH, TR, UA, VA”]
Antonio Micari (interventional cardiologist, Italy) gives his thoughts on the EMINENT RCT and whether it may have influenced his decision to use drug-eluting stents and drug coated balloons after a percutaneous transluminal angioplasty.
This video was filmed by Boston Scientific and is being sponsored for distribution in association with Interventional News. Biba Medical bears no responsibility for the assets used in the production of this video.
View the clinical trial results
Evidence in the SFA: Best strategy for treatment of the femoropopliteal segment
Evidence in the SFA: Considering the data when making decisions for patients
Evidence in the SFA: DES ‘will be the standard of care’ when treating SFA femoropopliteal lesions
[/geoip-content]
